JPMorgan Chase & Co. Has $45.35 Million Stake in Certara, Inc. (NASDAQ:CERT)

JPMorgan Chase & Co. lessened its position in Certara, Inc. (NASDAQ:CERT) by 4.4% in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 3,872,515 shares of the company’s stock after selling 176,780 shares during the period. JPMorgan Chase & Co. owned approximately 2.41% of Certara worth $45,347,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in CERT. Wasatch Advisors LP increased its holdings in Certara by 22.4% during the 3rd quarter. Wasatch Advisors LP now owns 9,015,941 shares of the company’s stock worth $105,577,000 after purchasing an additional 1,651,076 shares in the last quarter. Geneva Capital Management LLC grew its stake in Certara by 0.7% in the 3rd quarter. Geneva Capital Management LLC now owns 5,510,209 shares of the company’s stock valued at $64,525,000 after buying an additional 37,392 shares during the last quarter. Massachusetts Financial Services Co. MA raised its holdings in Certara by 40.7% in the 3rd quarter. Massachusetts Financial Services Co. MA now owns 3,901,898 shares of the company’s stock valued at $45,691,000 after acquiring an additional 1,128,006 shares during the period. State Street Corp lifted its position in Certara by 3.4% during the third quarter. State Street Corp now owns 3,679,699 shares of the company’s stock worth $43,089,000 after acquiring an additional 122,411 shares during the last quarter. Finally, Dimensional Fund Advisors LP boosted its stake in Certara by 9.7% in the 2nd quarter. Dimensional Fund Advisors LP now owns 3,079,023 shares of the company’s stock valued at $42,643,000 after purchasing an additional 273,095 shares during the period. 73.96% of the stock is currently owned by institutional investors.

Certara Stock Performance

Shares of Certara stock opened at $11.21 on Monday. The company has a current ratio of 2.86, a quick ratio of 2.86 and a debt-to-equity ratio of 0.28. Certara, Inc. has a 1-year low of $9.41 and a 1-year high of $19.87. The company has a market cap of $1.80 billion, a PE ratio of -56.05, a price-to-earnings-growth ratio of 5.86 and a beta of 1.53. The company has a 50 day moving average of $10.76 and a 200-day moving average of $12.08.

Certara (NASDAQ:CERT) last announced its quarterly earnings results on Wednesday, November 6th. The company reported $0.13 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.11 by $0.02. The company had revenue of $94.80 million during the quarter, compared to the consensus estimate of $95.51 million. Certara had a negative net margin of 8.34% and a positive return on equity of 3.43%. The company’s revenue for the quarter was up 10.7% compared to the same quarter last year. During the same period in the prior year, the business earned $0.06 earnings per share. As a group, equities research analysts forecast that Certara, Inc. will post 0.28 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several research analysts have weighed in on the company. Robert W. Baird lowered their price objective on Certara from $18.00 to $13.00 and set a “neutral” rating on the stock in a research report on Tuesday, November 5th. UBS Group raised shares of Certara from a “neutral” rating to a “buy” rating and set a $16.00 price target on the stock in a research report on Friday, September 27th. Finally, Barclays reduced their price target on Certara from $14.00 to $12.00 and set an “equal weight” rating on the stock in a research report on Thursday, November 7th. Six analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. Based on data from MarketBeat, Certara presently has a consensus rating of “Hold” and a consensus target price of $15.92.

Certara Profile

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.